Liraglutide 3.0 mg Reduces All Body Regions but Preserves Relative Lean Mass Over 35 Days | Research

The takeaway

Liraglutide 3.0 mg/day over 35 days reduced total, trunk, hip, and extremity mass, with slight absolute lean mass decrease but maintained relative lean mass and fat-free mass percentages.

Relative lean preserved
Despite absolute mass loss everywhere, lean and fat-free mass percentages remained stable — proportional shrinkage, not muscle wasting

What the researchers found

Liraglutide 3.0 mg reduced body weight, BMI, total mass, and regional mass (trunk, hip, extremities) over 35 days. Absolute fat-free and lean mass decreased slightly, but relative percentages remained stable.

Why it matters

Distinguishing between proportional mass loss and selective muscle wasting is crucial for understanding GLP-1 drug safety regarding body composition.

How the study worked

Secondary analysis of a crossover RCT with 20 obese adults receiving liraglutide 3.0 mg/day or placebo for 35 days, with DXA body composition and hormone measurements.

What this study cannot tell us

Short duration (35 days). Small sample. Secondary analysis. Long-term composition changes may differ as fat stores deplete.

How to read the evidence

Secondary analysis of crossover RCT. Important body composition data but short-term and small sample.

When this study was published

Published in 2025.

The bigger picture

The proportional mass loss pattern suggests GLP-1 drugs cause an overall "downsizing" rather than selective muscle destruction — a more reassuring interpretation.

Questions still open

Will proportional loss continue long-term, or will lean mass eventually decline disproportionately?
Does resistance exercise shift the ratio toward more fat loss?
Are there biomarkers predicting who will lose more lean mass?

Common questions

Does high-dose liraglutide cause muscle loss?

In absolute terms, lean mass decreased slightly over 35 days. However, the percentage of lean mass stayed the same — meaning the body lost fat and muscle proportionally. It is shrinking overall, not selectively losing muscle.

Should I worry about muscle on Saxenda?

Early data suggests proportional loss, which is reassuring. However, resistance exercise and adequate protein are still recommended to shift the balance toward more fat loss and better muscle preservation.

Read the original research

Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.

Diabetes research and clinical practice, 233, 113113

View on PubMed ↗Publisher’s paper ↗

Citation

Gutierrez de Piñeres, Valeria; Ramirez-Cisneros, Arantxa; Tamayo-Torres, Claudia S; Angelidi, Angeliki M; Kavelidou, Marianthi; Stefanakis, Konstantinos; Mantzoros, Christos S. (2026). Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.. Diabetes research and clinical practice, 233, 113113. https://doi.org/10.1016/j.diabres.2026.113113